A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Latest Information Update: 29 Oct 2022
At a glance
- Drugs ST 266 (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Sponsors Noveome
Most Recent Events
- 24 Oct 2022 Status changed from active, no longer recruiting to discontinued. (Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns)
- 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2022 Planned number of patients changed from 72 to 78.